Last Updated: June 17, 2026

ORAP Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

When do Orap patents expire, and when can generic versions of Orap launch?

Orap is a drug marketed by Teva, Concordia Pharms Inc, and Advanz Pharma. and is included in three NDAs.

The generic ingredient in ORAP is prednisolone sodium phosphate. There are eighty-eight drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Orap

A generic version of ORAP was approved as prednisolone sodium phosphate by BAUSCH AND LOMB on July 29^th, 1994.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for ORAP?
What are the global sales for ORAP?
What is Average Wholesale Price for ORAP?

Summary for ORAP

US Patents:	0
Applicants:	3
NDAs:	3

US Patents and Regulatory Information for ORAP

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	ORAP	pimozide	TABLET;ORAL	017473-003	Aug 27, 1997		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Advanz Pharma	ORAPRED ODT	prednisolone sodium phosphate	TABLET, ORALLY DISINTEGRATING;ORAL	021959-001	Jun 1, 2006		RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Teva	ORAP	pimozide	TABLET;ORAL	017473-001	Jul 31, 1984		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Concordia Pharms Inc	ORAPRED	prednisolone sodium phosphate	SOLUTION;ORAL	075117-001	Dec 14, 2000		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Advanz Pharma	ORAPRED ODT	prednisolone sodium phosphate	TABLET, ORALLY DISINTEGRATING;ORAL	021959-003	Jun 1, 2006		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Advanz Pharma	ORAPRED ODT	prednisolone sodium phosphate	TABLET, ORALLY DISINTEGRATING;ORAL	021959-002	Jun 1, 2006		RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.